Our governance

“Cédric Bisson has extensive experience across Canada, USA and Europe creating, building and advising businesses in biopharmaceuticals, healthcare and the innovation sector in general. He is passionate about growing Canada as a premier environment for innovation, and during his career has structured and executed over $3 B in transactions in funds and companies. Mr. Bisson is currently partner at Teralys Capital where he focuses on healthcare and life sciences investments, as well as growth opportunities. Teralys Capital is Canada’s largest private innovation-focused investor, financing funds and companies in IT, life sciences, and clean or industrial innovations, from early stage start-ups to expansion, growth and technology buy-outs. He was previously managing partner for life sciences at iNovia Capital in Montreal, Calgary and the USA, a private venture capital firm aimed at entrepreneurship and company building. Prior to this, he spent many years internationally at McKinsey & Company, a global management consulting firm, where he was a leader in the biopharma, healthcare and innovation practices in New York City, Paris, Montreal, and Toronto.”

“An accomplished scientist and leader, Diane Gosselin holds a Ph.D. in microbiology and immunology from Université de Montréal, as well as an Executive MBA from Université du Québec à Montréal (UQAM) and Université Paris-Dauphine. She has been very involved in the financing of innovative biomedical research for over 20 years. Previously working for Fonds de solidarité FTQ and PROCRÉA BioScience, Diane Gosselin work, since 2012, as the President and Chief Executive Officer of CQDM, she worked on the inception of CQDM when she joined the company in 2008 as Vice President, Research and Business Development. In fulfilling her mandate at CQDM, Diane Gosselin has demonstrated the relevance and value of CQDM’s model by building an impressive portfolio of 75 outstanding technologies that impact biopharmaceutical research ($89M committed), engaging a national network of over 1200 researchers from 69 research institutions (38 public and 31 private) and involving 140 mentors from CQDM’s pharmaceutical partners. She has raised $70M in funding from 13 of the largest pharmaceutical companies in the world, as well as from the Governments of Quebec and Canada. Moreover, she has been actively expanding CQDM’s reach and vision across Canada and internationally. Diane Gosselin currently sits on the Board of Montreal lnVivo, the Canadian Institutes of Health Research (CIHR), Ontario Genomics, CATALIS Quebec and CQDM. She has also Chaired the Board of Directors of CATALIS Quebec (2017-2019) and was a Board member of the Institut national de la recherche scientifique (INRS) (2018-2019).”

“In April 2020, Christine became the first General Manager and employee for Incyte Biosciences Canada. Prior to Incyte, Christine was CEO of Epigene Therapeutics, a spinout of Neomed, now Admare Bioinnovations. Prior to that, she spent eight years with Novartis as Canadian Commercial Head, Solid Tumors/Rare Disorders; General Manager – Oncology, Novartis Ireland; Head of Policy, Market Access, Stakeholder Relations, Novartis Oncology Canada. Christine also held leadership roles with Neurochem, Shire (now Takeda), BioChem Pharma and with the National Research Council of Canada (NRC) Industrial Research Assistance Program. Christine has been an advisor to life sciences startups and an executive-in-residence and advisor to healthcare venture capital teams at Business Development Bank of Canada (now Amplitude Ventures) and at Caisse de Dépôt et Placement du Québec. Christine holds an MBA and BSc from McGill University and her Institute of Corporate Directors designation (ICD.D) from Rotman School of Management, University of Toronto. Christine serves as a judge and mentor for McGill’s Dobson Centre for Entrepreneurship and McGill’s Desautels MBA School. Christine is a McGill Scarlet Key Award Recipient and was named a Healthcare Businesswomen Association Luminary in 2022. Christine is a Board member of Montréal inVivo, Innovative Medicines Canada and Research Canada.”

“Catherine Lunardi is the CEO and founder of GENAIZ. Ms. Lunardi has worked for over 20 years in a consulting and business analyst capacity, including as President of Uni3t, a consulting services company in the healthcare and life sciences sectors. Through her work with clients, Ms. Lunardi identified functional gaps in the software solutions available to the industry: “a lack of data to support decision-making” and “difficulty exploiting past data (especially those from failed projects).” Using her expertise and vast experience, she launched GENAIZ in 2016 to be an open and flexible platform based on artificial intelligence and concepts borrowed from neuroscience.”

“Gordon McCauley, BA, MBA, ICD.D was appointed President and CEO of adMare BioInnovations in 2016 after serving on the Board for four years. Mr. McCauley is an accomplished life science investor and executive. He has served as President and CEO of Viable Healthworks Corp., a national healthcare service business; Allon Therapeutics Inc., a neuroscience biotechnology company that developed novel therapeutics from pre-clinical to global phase 3 studies before being sold; and as Co-Founder and Partner of NDI Capital, an institutionally backed life-science investment fund. Mr. McCauley has also been a senior executive of several successful healthcare enterprises, and a senior advisor to several prominent Canadian political leaders. Mr. McCauley has served as a Director of a number of private and publicly traded companies. Currently, he is a Director of adMare (and a number of its portfolio and subsidiary companies), and Chairs the Board of both BIOTECanada, Canada’s national biotechnology industry organization, and CGEn, Canada’s national genomics enterprise. He has previously served as Chair of Life Sciences British Columbia, Acetech, The Toronto Rehab Foundation, and was a founding Director of the Toronto Rehabilitation Institute. In 2008, Mr. McCauley was the first Canadian appointed to the Board of The Biotechnology Industry Organization (BIO) in Washington D.C., where he served in leadership positions until 2013.”